Law ex­perts ar­gue that abor­tion drug with­draw­al would 'un­der­mine' the ap­proval process

More than a dozen food and drug law ex­perts ar­gued on Wednes­day that yank­ing the med­ica­tion abor­tion drug mifepri­s­tone from the mar­ket would “un­der­mine the drug ap­proval process far be­yond the con­text of mifepri­s­tone’s ap­proval.”

The com­ments are in re­sponse to a Texas law­suit chal­leng­ing the 2000 ap­proval of mifepri­s­tone, which is used in com­bi­na­tion with miso­pros­tol to end preg­nan­cies with­in the first 10 weeks. Nine­teen schol­ars from sev­er­al uni­ver­si­ties — in­clud­ing Har­vard and Stan­ford’s law schools — ar­gued in an am­i­cus brief that a pre­lim­i­nary or­der to with­draw mifepri­s­tone’s ap­proval would be “un­prece­dent­ed and in­ap­pro­pri­ate.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER